Progression to Microalbuminuria in Type 1 Diabetes: Development and Validation of a Prediction Rule
Overview
Authors
Affiliations
Aims/hypothesis: Microalbuminuria is common in type 1 diabetes and is associated with an increased risk of renal and cardiovascular disease. We aimed to develop and validate a clinical prediction rule that estimates the absolute risk of microalbuminuria.
Methods: Data from the European Diabetes Prospective Complications Study (n = 1115) were used to develop the prediction rule (development set). Multivariable logistic regression analysis was used to assess the association between potential predictors and progression to microalbuminuria within 7 years. The performance of the prediction rule was assessed with calibration and discrimination (concordance statistic [c-statistic]) measures. The rule was validated in three other diabetes studies (Pittsburgh Epidemiology of Diabetes Complications [EDC] study, Finnish Diabetic Nephropathy [FinnDiane] study and Coronary Artery Calcification in Type 1 Diabetes [CACTI] study).
Results: Of patients in the development set, 13% were microalbuminuric after 7 years. Glycosylated haemoglobin, AER, WHR, BMI and ever smoking were found to be the most important predictors. A high-risk group (n = 87 [8%]) was identified with a risk of progression to microalbuminuria of 32%. Predictions showed reasonable discriminative ability, with c-statistic of 0.71. The rule showed good calibration and discrimination in EDC, FinnDiane and CACTI (c-statistic 0.71, 0.79 and 0.79, respectively).
Conclusions/interpretation: We developed and validated a clinical prediction rule that uses relatively easily obtainable patient characteristics to predict microalbuminuria in patients with type 1 diabetes. This rule can help clinicians to decide on more frequent check-ups for patients at high risk of microalbuminuria in order to prevent long-term chronic complications.
Machine Learning-Driven Prediction of Comorbidities and Mortality in Adults With Type 1 Diabetes.
Andersen J, Stoltenberg C, Jensen M, Vestergaard P, Hejlesen O, Hangaard S J Diabetes Sci Technol. 2024; :19322968241267779.
PMID: 39091237 PMC: 11571562. DOI: 10.1177/19322968241267779.
Biomarkers of diabetic kidney disease.
Colhoun H, Marcovecchio M Diabetologia. 2018; 61(5):996-1011.
PMID: 29520581 PMC: 6448994. DOI: 10.1007/s00125-018-4567-5.
Cigarette Smoking, Diabetes, and Diabetes Complications: Call for Urgent Action.
Zhu P, Pan X, Sheng L, Chen H, Pan A Curr Diab Rep. 2017; 17(9):78.
PMID: 28766247 DOI: 10.1007/s11892-017-0903-2.
Miller R, Anderson S, Costacou T, Sekikawa A, Orchard T Diab Vasc Dis Res. 2016; 13(4):250-9.
PMID: 27190081 PMC: 5374723. DOI: 10.1177/1479164116629353.
Razanskaite-Virbickiene D, Danyte E, Zalinkevicius R BMC Nephrol. 2016; 17:38.
PMID: 27036319 PMC: 4815109. DOI: 10.1186/s12882-016-0252-4.